Growth and Metabolic Response to GH and GnRHa Treatment Versus GH Alone in Boys Born SGA.

• IGF-1 concentration [ Time Frame: every 6 monthes, during all study period ] [ Designated as safety issue: Yes ]
• Hormone profile, Lipid and lipoprotein concentrations [ Time Frame: once a year during all study period ] [ Designated as safety issue: No ]
• Prepubertal changes [ Time Frame: every 3 monthes during all study peiod ] [ Designated as safety issue: No ]
• Bone age [ Time Frame: once a year, during all study period ] [ Designated as safety issue: No ]
• quality of life questionnaire [ Time Frame: once a year, during all study period ] [ Designated as safety issue: No ]
• Psychological questionnaire [ Time Frame: once a year, during all study peiod ] [ Designated as safety issue: No ]

• hormone profile [ Time Frame: once a year during all study period ]
• IGF-1 concentration [ Time Frame: every 6 monthes, during all study period ]
• Lipid and lipoprotein concentrations [ Time Frame: once a year during all study period ]
• Prepubertal changes [ Time Frame: every 3 monthes during all study peiod ]
• Bone age [ Time Frame: once a year, during all study period ]
• quality of life questionnaire [ Time Frame: once a year, during all study period ]
• appetite questionnaire [ Time Frame: once a year, during all study period ]
• Psychological questionnaire [ Time Frame: once a year, during all study peiod ]

A 2-arms randomized open prospective intervention study to determine the Growth and metabolic response to growth hormone and gonadotropin-releasing hormone agonist treatment versus growth hormone alone in boys born SGA.

All subjects will be treated with NorditropinSimplex at a dosage of 100mcg/kg/d.

At onset of puberty, subjects will be randomized into either combined treatment with GH and GnRHa or GH alone.

A 2-arms randomized open prospective intervention study including 20 boys, in order to determine the effect of growth hormone (GH) and gonadotropin-releasing hormone agonist treatment versus growth hormone (GnRHa) alone on growth and metabolic response.

Objectives:

The primary objective is to investigate the effect of delaying the pubertal process by pubertal suppression on growth and final height of boys who were born SGA and treated with GH.

The secondary objectives are to determine the metabolic effect of the combined therapy of GH plus gonadotropin agonists to that of GH alone on the dietary intake, serum leptin, ghrelin, IGF-1, lipid and lipoprotein concentrations prior to and during treatment, and to assess the quality of life between the two groups.

Study population:

20 prepubertal boys.

Inclusion Criteria:

1. Ages 10-13
2. IUGR
3. Height of at least 2 standard deviations below the mean height for chronological age and sex according to the 2000 standards from the Centers for Disease Control and Prevention (CDC).
4. prepubertal(Tanner stage 1) at commencement of trail.
5. Peak GH above 10ng/ml in at least one provocative test for GH secretion.
6. Signed informed consent form.

Exclusion criteria:

1. Growth retardation associated with malignancy, severe chronic disease, genetic syndromes and endocrine disorders.
2. Diabetes.
3. Treatment with any medical product which may interfere with GH effects.

Trail design:

A prospective, randomized controlled study assessing the impact of two years of combined treatment with GH and GnRHa on height of boys with severe growth failure due to SGA with height >2.25 SDS , compared with GH alone.

All subjects will be treated with NorditropinSimplex at a dosage of 100mcg/kg/d. At onset of puberty (testicular volume greater than 4 ml in consecutive examinations) subjects will be randomized into either combined treatment with GH and GnRHa or GH alone.

Methods:

1. Urine test will be held every three months.
2. X-ray photograph for bone age determination will be taken at baseline and every year after.
3. Blood will be taken at baseline and every year after in order to evaluate the following parameters: Lipid and lipoprotein concentrations, ghrelin, leptin, glucose, insulin and HbA1c.
4. Blood will be taken on randomization visit and three months after in order to evaluated the following parameters: LH, FSH and Testosterone
5. Blood will be taken at baseline and every half a year after to evaluate levels of IGF-1.
6. For evaluation of the growth hormone response, additional blood tests will be preformed one month and three months after treatment with growth hormone.
7. On every blood and urine that will be taken, proteomic analysis will be held.
8. Before treatment with growth hormone, one year after treatment and in the end of the study quality of life questionnaire, appetite questionnaire and Psychological questionnaires will be filled.

The safety of growth hormone treatment will be assessed from:

1. Monitoring of adverse events.
2. Measurement of HbA1c.
3. Measurement of hematology, serum biochemistry and urinalysis laboratory variables.
4. Measurement of fasting glucose and insulin concentrations.
5. IGF-1
6. Physical examinations and measurements of vital signs height and body weight.
7. Measurement of bone age.

• Drug: growth hormone and gonadotropin-releasing hormone agonist
  GH & GNRHa treatment
• Drug: growth hormone
  GH treatment

• Experimental: 1
  GH & GNRHa treatment
  Intervention: Drug: growth hormone and gonadotropin-releasing hormone agonist
• Active Comparator: 2
  GH treatment
  Intervention: Drug: growth hormone

Inclusion Criteria:

1. Boys
2. IUGR
3. Ages 10-13
4. height of at list 2.0 standard deviations below the mean height for chronological age and sex according to the 2000 standards from the Centers for Disease Control and Prevention (CDC)
5. Prepubertal (tanner stage 1) at commencement of trail
6. Peak GH above 10ng/ml in at least one provocative test for GH secretion 7.Signed informed consent

Exclusion Criteria:

1. Growth retardation associated with malignancy, severe chronic disease, genetic syndromes and endocrine disorders
2. Diabetes
3. Treatment with any medical product which may interfere with GH effects